Expresses optimized PdCO in frame with EGFP under control of minimal CamKIIa promotor.

Expresses optimized PdCO in frame with mScarlet under control of human synapsin1 promotor after Cre-dependent recombination.

Expresses optimized PdCO in frame with mScarlet under control of human synapsin1 promotor.

Expresses optimized PdCO in frame with mScarlet under control of eukaryotic Ef1a promoter after Flp-dependent recombination.

Expresses optimized PdCO in frame with mScarlet under control of minimal CamKIIa promotor.

Expresses optimized PdCO in frame with EGFP under control of human synapsin1 promotor.

Expresses optimized PdCO in frame with mScarlet under control of human synapsin1 promotor after Cre-dependent recombination.

Expresses optimized PdCO in frame with EGFP under control of minimal CamKIIa promotor.

Expresses optimized PdCO in frame with mScarlet under control of eukaryotic Ef1a promoter after Cre-dependent recombination.

Expresses bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized PdCO under control of human synapsin1 promotor after Cre-dependent recombination

Expresses optimized PdCO in frame with mScarlet under control of eukaryotic Ef1a promoter after Cre-dependent recombination.

Expresses bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized PdCO under control of minimal CamKIIa promotor

AAV transfer plasmid containing H2B fused piggyBac self-reporting transposon with tdTomato marker for mammalian calling cards

AAV transfer plasmid containing a constitutive (non Cre-dependent) BrokenHeart construct: a piggyBac donor transposon interrupting tdTomato. Transposase activity rescues coding sequence.

Ready-to-use AAV5 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet.These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.